OrbiMed Israel GP Ltd.
Known title: 10% OwnerCIK: 0001569590
Associated companies
Transaction History
| CMMB | ▼ Sell | Open Market | 266,376 | $890K | 1/3/2023 | View on chart |
| CMMB | ▼ Sell | Open Market | 70,524 | $318K | 1/3/2023 | View on chart |
| CMMB | ▲ Buy | Grant | 288,170 | $5.0M | 3/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Chemomab Amends Merger Agreement for U.S. Redomiciliation
Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.
Chemomab Amends Merger Agreement for U.S. Redomiciliation. Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.